Chinook Therapeutics Inc

Muddy Waters remains short Chinook Therapeutics Inc (NASDAQ:KDNY).  In addition to distorting clinical trial data, Chinook has manipulated its financials.  The misleading – if not improper – accounting, which seems an attempt to make Chinook appear more substantive than it is, primarily relates to t… more

Muddy Waters is short Chinook Therapeutics Inc (NASDAQ:KDNY) because we believe it is highly unlikely that atrasentan, its lead product candidate, will be approved by the FDA.  We conclude that atrasentan is inefficacious for chronic kidney disease. We also conclude that atrasentan has been shown to… more